GW Pharmaceuticals (NASDAQ:GWPH) posted its earnings results on Sunday. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.31, Fidelity Earnings reports. GW Pharmaceuticals had a negative net margin of 11.05% and a negative return on equity of 7.46%.
NASDAQ GWPH opened at $219.28 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 5.13. The firm has a 50-day simple moving average of $217.57 and a 200 day simple moving average of $163.58. GW Pharmaceuticals has a twelve month low of $87.07 and a twelve month high of $219.57. The stock has a market cap of $6.87 billion, a PE ratio of -127.49 and a beta of 2.15.
Several equities analysts have commented on the stock. Northland Securities downgraded shares of GW Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 3rd. Morgan Stanley restated an "equal weight" rating and set a $220.00 price target (up from $193.00) on shares of GW Pharmaceuticals in a report on Thursday, February 4th. Raymond James restated a "hold" rating on shares of GW Pharmaceuticals in a report on Monday, February 22nd. Citigroup cut shares of GW Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Thursday, February 4th. Finally, HC Wainwright cut shares of GW Pharmaceuticals from a "buy" rating to a "neutral" rating and upped their price target for the company from $162.00 to $220.00 in a report on Thursday, February 4th. Eleven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of "Hold" and an average price target of $197.75.
In related news, Director Volker Knappertz sold 3,060 shares of the stock in a transaction dated Friday, March 26th. The shares were sold at an average price of $18.10, for a total value of $55,386.00. Following the completion of the transaction, the director now owns 92,412 shares of the company's stock, valued at $1,672,657.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cabot Brown sold 4,020 shares of the stock in a transaction dated Thursday, March 18th. The stock was sold at an average price of $17.95, for a total transaction of $72,159.00. Following the completion of the transaction, the director now directly owns 7,200 shares of the company's stock, valued at approximately $129,240. The disclosure for this sale can be found here. Insiders sold 15,480 shares of company stock valued at $279,753 in the last three months. Company insiders own 3.10% of the company's stock.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
Read More: Net Income
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is diluted earnings per share (Diluted EPS)?7 Undervalued Stocks That Deserve More Attention
With the Dow Jones Industrial Average (DJIA) hitting new highs seemingly every day, it may seem like the wrong time to be looking at undervalued stocks. Or is it?
From cannabis to cryptocurrencies, and let’s not forget electric vehicles the market seems to be blowing bubbles wherever you look. And that’s why now may be exactly the right time to zig while the market is sagging. And that means looking for undervalued stocks.
But finding undervalued stocks is subjective. Some analysts use specific fundamental metrics. Others use technical analysis.
However, the general idea is that you’re looking for stocks that are trading below their fair value.
In some cases, these may be stocks whose financials are stronger than other stocks in their sector, but it’s trading at a lower price. In other cases, a company may have potential that is not reflected in its stock price. Put another way, undervalued stocks are stocks that have room to grow. That’s why they deserve a place in your portfolio.
And that’s why we’ve put together this special presentation on stocks that are undervalued right at this time. An investment in these companies is likely to be rewarded because the stocks are moving under the radar from the broader market.
View the "7 Undervalued Stocks That Deserve More Attention"